178 related articles for article (PubMed ID: 36831678)
1. Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant
Ha S; Wang BD
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831678
[TBL] [Abstract][Full Text] [Related]
2. Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers.
Ha S; Gujrati H; Wang BD
Front Endocrinol (Lausanne); 2023; 14():1190479. PubMed ID: 37670888
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.
Wang BD; Ceniccola K; Hwang S; Andrawis R; Horvath A; Freedman JA; Olender J; Knapp S; Ching T; Garmire L; Patel V; Garcia-Blanco MA; Patierno SR; Lee NH
Nat Commun; 2017 Jun; 8():15921. PubMed ID: 28665395
[TBL] [Abstract][Full Text] [Related]
4. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
5. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
Zhu J; Ke K; Xu L; Jin J
J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
[TBL] [Abstract][Full Text] [Related]
6. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
[TBL] [Abstract][Full Text] [Related]
7. A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance.
Olender J; Wang BD; Ching T; Garmire LX; Garofano K; Ji Y; Knox T; Latham P; Nguyen K; Rhim J; Lee NH
Mol Cancer Res; 2019 Oct; 17(10):2115-2125. PubMed ID: 31266816
[TBL] [Abstract][Full Text] [Related]
8. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib.
Zhou XR; Li X; Liao LP; Han J; Huang J; Li JC; Tao HR; Fan SJ; Chen ZF; Li Q; Chen SJ; Ding H; Yang YX; Zhou B; Jiang HL; Chen KX; Zhang YY; Huang CX; Luo C
Acta Pharmacol Sin; 2022 Feb; 43(2):457-469. PubMed ID: 33850273
[TBL] [Abstract][Full Text] [Related]
9. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
11. Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
Li D; Tian G; Wang J; Zhao LY; Co O; Underill ZC; Mymryk JS; Claessens F; Dehm SM; Daaka Y; Liao D
Prostate; 2018 Nov; 78(15):1140-1156. PubMed ID: 30009471
[TBL] [Abstract][Full Text] [Related]
12. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3K
Allen RA; Brookings DC; Powell MJ; Delgado J; Shuttleworth LK; Merriman M; Fahy IJ; Tewari R; Silva JP; Healy LJ; Davies GCG; Twomey B; Cutler RM; Kotian A; Crosby A; McCluskey G; Watt GF; Payne A
J Pharmacol Exp Ther; 2017 Jun; 361(3):429-440. PubMed ID: 28442583
[TBL] [Abstract][Full Text] [Related]
13. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure.
Jia W; Luo S; Zhao W; Xu W; Zhong Y; Kong D
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234743
[TBL] [Abstract][Full Text] [Related]
15. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.
Redenbaugh V; Coulter T
Front Pediatr; 2021; 9():702872. PubMed ID: 34422726
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors.
Feng Y; Duan W; Fan S; Zhang H; Zhang SQ; Xin M
Bioorg Med Chem; 2019 Oct; 27(19):115035. PubMed ID: 31434616
[TBL] [Abstract][Full Text] [Related]
17. Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.
Yeon JT; Kim KJ; Son YJ; Park SJ; Kim SH
Arch Pharm Res; 2019 Aug; 42(8):712-721. PubMed ID: 31161369
[TBL] [Abstract][Full Text] [Related]
18. The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL.
Adam E; Kim HN; Gang EJ; Schnair C; Lee S; Lee S; Khazal S; Kosoyan O; Konopleva M; Parekh C; Bhojwani D; Wayne AS; Abdel-Azim H; Heisterkamp N; Kim YM
Cancers (Basel); 2017 Sep; 9(9):. PubMed ID: 28891959
[TBL] [Abstract][Full Text] [Related]
19. Puquitinib, a novel orally available PI3Kδ inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia.
Xie C; He Y; Zhen M; Wang Y; Xu Y; Lou L
Cancer Sci; 2017 Jul; 108(7):1476-1484. PubMed ID: 28418085
[TBL] [Abstract][Full Text] [Related]
20. BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3Kδ inhibitors by suppressing PI3K reactivation and c-MYC expression.
Zuo W; Zhu Y; Liu Z; Xia Y; Xu Y; Peng C; Yu L; Wang N
Am J Cancer Res; 2021; 11(1):215-235. PubMed ID: 33520370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
